Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Tumor Immune Microenvironment and Novel Strategies for Cancer Immunotherapy
share announcement

Tumor Immune Microenvironment and Novel Strategies for Cancer Immunotherapy

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (30 April 2025) | Viewed by 4482

Special Issue Editor

Dr. Sidra Islam

E-Mail Website
Guest Editor
Department of Pathology, Case Western Reserve University, Cleveland, OH, USA
Interests: protein biophysics; protein protein interactions; antioxidants; heme proteins; gamma crystallins

Special Issue Information

Dear Colleagues,

The Special Issue “Tumor Immune Microenvironment and Novel Strategies for Cancer Immunotherapy” encompasses a multidisciplinary field at the intersection of oncology, immunology, and therapeutics. It involves the study of complex interactions between cancer cells and the immune system within the microenvironment of tumors, as well as the development and implementation of innovative approaches to harness the immune system for treating cancer. The scope of this Special Issue includes investigating the cellular and molecular components of the tumor microenvironment, including tumor-infiltrating immune cells (such as T cells, B cells, natural killer cells, and myeloid cells), stromal cells, cytokines, chemokines, and extracellular matrix components; identifying biomarkers and predictive signatures associated with the tumor immune microenvironment; novel strategies for cancer immunotherapy aiming to manipulate the tumor immune microenvironment to enhance anti-tumor immune responses and overcoming immune evasion mechanisms employed by cancer cells; recognizing the complexity of the tumor immune microenvironment; combinatorial approaches that integrate immunotherapy with conventional treatments (such as chemotherapy, radiation therapy, and targeted therapy) or other immunomodulatory agents; combination therapies which have the potential to synergistically enhance therapeutic efficacy and overcome resistance mechanisms; translating preclinical findings and novel immunotherapeutic strategies into clinical practice, which requires rigorous clinical trials, biomarker validation studies, and collaborative efforts between researchers, clinicians, regulatory agencies, and industry partners.

In summary, this Special Issue encompasses a broad spectrum of research aimed at elucidating the complex interplay between tumors and the immune system, as well as the development of innovative immunotherapeutic approaches to combat cancer.

Dr. Sidra Islam
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor microenvironment cancer immunotherapy
  • immune markers
  • tumor infilterating immune cells
  • tumors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

28 pages, 19771 KiB  
Article
Pan-Cancer Characterization Identifies SLC19A1 as an Unfavorable Prognostic Marker and Associates It with Tumor Infiltration Features
by Yimin Pan, Zhichen Liu and Changwu Wu
Biomedicines 2025, 13(3), 571; https://doi.org/10.3390/biomedicines13030571 - 25 Feb 2025
Viewed by 683
Abstract
Background: Recent studies have identified solute carrier family 19 member 1 (SLC19A1) as a second messenger transporter that regulates massive immune-related signaling cascades, but current studies provide limited information. This study aims to evaluate its role and the potential mechanisms across various cancers. [...] Read more.
Background: Recent studies have identified solute carrier family 19 member 1 (SLC19A1) as a second messenger transporter that regulates massive immune-related signaling cascades, but current studies provide limited information. This study aims to evaluate its role and the potential mechanisms across various cancers. Methods: We analyzed multi-omics data from a pan-cancer cohort to evaluate SLC19A1 expression and its association with multiple features, including prognosis, tumor stemness, genome instability, and immune infiltration. Immunofluorescence staining was performed to validate SLC19A1 expression in tumor tissues and its relationship M2 macrophages. In addition, we used web tools such as ROCplotter to evaluate the association between SLC19A1 and response to chemotherapy and immunotherapy. Results: SLC19A1 was found to be overexpressed in multiple cancer types compared to normal tissues, correlating with poor prognosis. High SLC19A1 levels were associated with increased genomic instability and immune suppression. In addition, SLC19A1 was negatively correlated with CD8+ T-cell infiltration and positively correlated with M2 macrophage infiltration. The association of SLC19A1 with M2 macrophages was confirmed in multiple immunofluorescence staining. Finally, SLC19A1 was associated with the response to chemotherapy and immunotherapy in a variety of tumors. Conclusions: Our findings position SLC19A1 as a novel unfavorable prognostic marker in cancer, closely linked to immune suppression and genomic instability. This study highlights the need for further exploration of SLC19A1 as a therapeutic target and its implications in cancer treatment strategies. Full article
(This article belongs to the Special Issue Tumor Immune Microenvironment and Novel Strategies for Cancer Immunotherapy)
►▼ Show Figures

Figure 1

15 pages, 13837 KiB  
Article
Cordycepin Augments the Efficacy of Anti-PD1 against Colon Cancer
by Wen-Kuei Chang, Yen-Ting Chen, Chin-Ping Lin, Chia-Jung Wang, Hui-Ru Shieh, Chih-Wen Chi, Tung-Hu Tsai and Yu-Jen Chen
Biomedicines 2024, 12(7), 1568; https://doi.org/10.3390/biomedicines12071568 - 15 Jul 2024
Cited by 1 | Viewed by 1586
Abstract
Colon cancer has a poor clinical response to anti-PD1 therapy. This study aimed to evaluate the effect of cordycepin on the efficacy of anti-PD1 treatment in colon cancer. The viability of CT26 mouse colon carcinoma cells, cell-cycle progression, morphology, and the expression of [...] Read more.
Colon cancer has a poor clinical response to anti-PD1 therapy. This study aimed to evaluate the effect of cordycepin on the efficacy of anti-PD1 treatment in colon cancer. The viability of CT26 mouse colon carcinoma cells, cell-cycle progression, morphology, and the expression of mRNA and protein were assessed. A syngeneic animal model was established by implanting CT26 cells into BALB/c mice for in vivo experiments. Multi-parameter flow cytometry was used to analyze the splenic cell lineages and tumor microenvironment (TME). The in vitro data revealed that cordycepin, but not adenosine, inhibited CT26 cell viability. The protein, but not mRNA, expression levels of A2AR and A2BR were suppressed by cordycepin but not by adenosine in CT26 cells. The combination of cordycepin, but not adenosine, with anti-PD1 exhibited a greater tumor-inhibitory effect than anti-PD1 alone as well as inhibited the expression of A2AR and A2BR in splenic macrophages. In the TME, the combination of cordycepin and anti-PD1 increased the number of CD3+ T cells and neutrophils and decreased the number of natural killer (NK) cells. Overall, cordycepin augmented the antitumor effects of anti-PD1 against mouse colon carcinoma cells and inhibited the expression of the adenosine receptors A2AR and A2BR in splenic macrophages and intratumoral NK cells. Full article
(This article belongs to the Special Issue Tumor Immune Microenvironment and Novel Strategies for Cancer Immunotherapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 1061 KiB  
Review
Coley’s Toxin to First Approved Therapeutic Vaccine—A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment
by K. Devaraja, Manisha Singh, Krishna Sharan and Sadhna Aggarwal
Biomedicines 2024, 12(12), 2746; https://doi.org/10.3390/biomedicines12122746 - 30 Nov 2024
Cited by 2 | Viewed by 1613
Abstract
Cancer immunobiology is one of the hot topics of discussion amongst researchers today, and immunotherapeutic modalities are among the selected few emerging approaches to cancer treatment that have exhibited a promising outlook. However, immunotherapy is not a new kid on the block; it [...] Read more.
Cancer immunobiology is one of the hot topics of discussion amongst researchers today, and immunotherapeutic modalities are among the selected few emerging approaches to cancer treatment that have exhibited a promising outlook. However, immunotherapy is not a new kid on the block; it has been around for centuries. The origin of cancer immunotherapy in modern medicine can be traced back to the initial reports of spontaneous regression of malignant tumors in some patients following an acute febrile infection, at the turn of the twentieth century. This review briefly revisits the historical accounts of immunotherapy, highlighting some of the significant developments in the field of cancer immunobiology, that have been instrumental in bringing back the immunotherapeutic approaches to the forefront of cancer research. Some of the topics covered are: Coley’s toxin—the first immunotherapeutic; the genesis of the theory of immune surveillance; the discovery of T lymphocytes and dendritic cells and their roles; the role of tumor antigens; relevance of tumor microenvironment; the anti-tumor (therapeutic) ability of Bacillus Calmette– Guérin; Melacine—the first therapeutic vaccine engineered; theories of immunoediting and immunophenotyping of cancer; and Provenge—the first FDA-approved therapeutic vaccine. In this review, head and neck cancer has been taken as the reference tumor for narrating the progression of cancer immunobiology, particularly for highlighting the advent of immunotherapeutic agents. Full article
(This article belongs to the Special Issue Tumor Immune Microenvironment and Novel Strategies for Cancer Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop